Leuprolide vs Triptorelin

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicLeuprolideTriptorelin
What it is

A GnRH agonist. The Eligard label describes leuprolide acetate as a synthetic nonapeptide analogue of GnRH that is more potent than the natural hormone.1

A synthetic decapeptide agonist analogue of GnRH, the hypothalamic hormone that controls the pituitary’s reproductive hormones, according to the label.7

FDA status

FDA-approved

FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products1,2,3,4,5,6

FDA-approved. Drugs@FDA lists Lupron with an original approval date of April 9, 1985, and Eligard with one of January 23, 2002, among many leuprolide applications. The cited Eligard label has no boxed warning.1,2,4

Is leuprolide FDA-approved?

FDA-approved

FDA-approved as Trelstar for advanced prostate cancer7,8

FDA-approved. Drugs@FDA lists Trelstar with an original approval date of June 15, 2000, for advanced prostate cancer. The cited label has no boxed warning.7,8

Is triptorelin FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.9

Not among the six peptides the policy lists.9

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Limited human data

  • Small, short, or incompletely reported human study Four open-label studies described in the Eligard label, one for each of its formulations, in 120, 117, 90 and 111 men with prostate cancer, with suppression of testosterone to castrate levels as the main measure.1

Large randomized human trials

  • Large randomized human trial A randomized, active-controlled trial in 346 participants, all men with advanced prostate cancer, comparing two Trelstar versions, described in the label as a basis of its effectiveness.7
  • Controlled human trial A randomized, active-controlled trial in 277 men with advanced prostate cancer comparing Trelstar with another approved GnRH agonist, described in the label.7
  • Small, short, or incompletely reported human study A single-arm trial in 120 men with advanced prostate cancer, described in the label.7
Records collected

117 ClinicalTrials.gov records and 48 PubMed records collected

30 ClinicalTrials.gov records and 30 PubMed records collected

Area of study

Sexual and reproductive health, Cancer

Hormones, Cancer7

Latest dated events
  1. FDA approves Vobrig for central precocious puberty in children.5,6
  2. DailyMed publishes the Eligard label version cited on this page.1
  3. FDA approves Fensolvi, according to Drugs@FDA.10
  1. DailyMed publishes the Trelstar label version cited on this page.7
  2. FDA approves Trelstar, according to Drugs@FDA.8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ELIGARD (leuprolide acetate) injection, suspension, extended release · SPL version 19 · published 2026-05-11 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Drugs@FDA application NDA019732 · original submission status AP · 1989-01-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    Drugs@FDA application NDA213225 · original submission status AP · 2026-08-26 · dataset 2026-11-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked November 15, 2026

  7. 7
    TRELSTAR (triptorelin pamoate) kit · SPL version 20 · published 2026-07-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  8. 8
    Drugs@FDA: TRELSTAR (triptorelin pamoate), NDA 020715 · original approval June 15, 2000 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  9. 9
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  10. 10
    Drugs@FDA application NDA213150 · original submission status AP · 2020-05-01 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026